Because overexpression of Bcl-xL is one of the hallmarks of cancer7, Bcl-xL is considered to be an important drug target, whereby an BH3-mimic inhibitor that binds to the BH3 binding site would be able to prevent Bcl-xL from inhibiting apoptotic signals, halting the growth of cancer cells. Here, BCL2L1 is linked to cancer.